Cerus Corp (CERS) stock
Close on Nov 11, 2026Market cap $427.23MP/E –Yield –
Cerus Corp reported revenue of $254.23M for the twelve months to Sep 30, 2026. Free cash flow was $494.00K, up 194.0% from a year earlier. At the latest close the market valued the company at $427.23M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $427.23M
- P/E ratio
- –
- Price to sales
- 1.68
- Price to book
- 5.64
- Dividend yield
- –
- Free cash flow yield
- 0.12%
Fundamentals
- Revenue
- $254.23M
- Net income
- -$7.31M
- EPS, diluted
- -$0.03
- Free cash flow
- $494.00K
- Book value per share
- $0.38
- Diluted shares
- 202M
Trading
- Next earnings
- Mar 1, 2027 (estimated, during market hours)
- Previous close
- $1.95
- Open
- $2.02
- Day's range
- $2.00 – $2.16
- Volume
- 2,237,789
- Average volume (20 days)
- 2,383,396
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.72
- 52-week range
- $1.47 – $3.47
- RSI (14 days)
- 42.6
- Volatility (1 year)
- 74.9%
- Relative volume
- 1.02×
- WACC
- 13.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CERS | S&P 500 | Difference | CERS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.8% | -2.4% | −5.4 pts | ||
| 3 months | -17.3% | -1.2% | −16.2 pts | ||
| Year to date | +2.9% | +12.3% | −9.4 pts | ||
| 1 year | +28.5% | +12.4% | +16.0 pts | ||
| 3 years | +32.5% | +78.8% | −46.3 pts | +9.8% | +21.4% |
| 5 years | -71.0% | +75.2% | −146.2 pts | -21.9% | +11.9% |
| 10 years | -63.2% | +311.1% | −374.3 pts | -9.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cerus filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Cerus
Surgical & Medical Instruments & Apparatus
Cerus Corporation is a biomedical company focused on the field of blood transfusion safety. The company develops and commercializes the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections by targeting and inactivating pathogens such as viruses, bacteria, and parasites in donated blood components. Its commercial product line includes systems for platelets, plasma, and cryoprecipitation, while a pathogen reduction system for red blood cells remains in development. The company’s primary customers and end users include blood centers, hospitals, clinicians, and governmental entities such as the Biomedical Advanced Research and Development Authority and the United States Department of Defense.
Company profile, executives and historyCerus stock: common questions
What is Cerus's stock price?
CERS closed at $2.12 on Nov 11, 2026, up 8.72% on the day. Over the past 52 weeks it traded between $1.47 and $3.47.
What is Cerus's market cap?
Cerus was worth $427.23M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CERS's P/E ratio?
Cerus lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.03), so it has no meaningful P/E ratio.
How much revenue does Cerus make?
Cerus reported revenue of $254.23M for the twelve months to Sep 30, 2026.
Does Cerus pay a dividend?
No. Cerus has not paid a cash dividend over the last twelve months.
When does Cerus report earnings next?
Cerus is expected to report Q4 FY2026 results on Mar 1, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CERS stock performed over the past year?
Including dividends, CERS returned +28.5% over the past year, against +12.4% for the S&P 500.
How many CERS shares are sold short?
15M shares were sold short at the latest FINRA report, 7.72% of the float, or 8.2 days of average trading volume.
Who are Cerus's competitors?
Companies most similar to Cerus by business, industry and size include MDXG, LMAT, PRCT, ANGO, SIBN.
See a number that looks wrong?